Semaglutide at 10 Weeks: What Results Does the Evidence Show?

What STEP 1 shows about the early months of treatment

The STEP 1 trial followed 1,961 adults over 68 weeks, comparing semaglutide 2.4mg against placebo alongside lifestyle support. The average weight reduction across the full trial was approximately 15% of body weight, a figure that drew significant clinical attention. But the trial's trajectory matters as much as its endpoint. Weight loss was not front-loaded; it built steadily, with the steepest relative gains occurring as participants moved through dose escalation and into maintenance.

At week 10, most participants on the standard titration schedule would be at or approaching the 1mg dose, with the 1.7mg and 2.4mg steps still ahead. The NHS semaglutide medicines page describes the standard escalation (starting at 0.25mg and stepping up roughly every four weeks) which means week 10 represents early progress, not a plateau. Appetite suppression is usually tangible by this point. Visible scale changes vary considerably between individuals and depend partly on how much dose has been reached by week 10.

A helpful practical habit: photograph your weekly dose packaging when you inject each week, a quick visual log that takes under a minute and helps you track exactly how many weeks of each dose you have completed if questions arise at a clinical review.

Why the 10-week figure is not a reliable personal benchmark

It is tempting to treat week 10 as a milestone for comparison, to measure yourself against a clinical trial average and draw conclusions. The difficulty is that trial averages smooth out enormous individual variation. In STEP 1, responses ranged from very modest early losses to substantial reductions; some participants had lost noticeably more by week 10 than others who would ultimately achieve similar 68-week results. Titration pace, gastrointestinal tolerance, and baseline factors all shift the timeline.

For a fuller sense of how results tend to unfold across the first weeks, the week-by-week breakdown on this site walks through what the evidence shows at each stage. If you are trying to gauge whether your own experience is on track, that week-by-week view offers more texture than a single ten-week snapshot. The question of whether progress is sufficient (and whether titration should continue) belongs with your prescriber, who can review your specific situation rather than a population average. You can also read about what many people notice specifically at eight weeks, which is the closest preceding point with its own clinical context.

Side effects commonly present at 10 weeks

The gastrointestinal side-effect profile of semaglutide is well-documented. Nausea, constipation, loose stools, indigestion, and reduced appetite are reported frequently, particularly after dose increases. At week 10, many people are mid-escalation, which means they may be experiencing a fresh round of these effects after stepping up. For most people, GI symptoms settle within days to roughly two weeks of each dose change, though this varies.

The MHRA monitors semaglutide closely as a Black Triangle medicine. In January 2026 the MHRA issued a Drug Safety Update on GLP-1 medicines, highlighting that acute pancreatitis (though infrequent) can be serious: severe stomach pain reaching the back, with or without vomiting, warrants urgent medical assessment rather than waiting to see whether it passes. Any suspected side effects can be reported through the MHRA Yellow Card scheme, which remains open to patients and carers throughout treatment. For most people at week 10, side effects are manageable; if they are not, that is a conversation to have with your prescriber rather than a reason to adjust the dose independently.

What to expect beyond week 10, and how clinical review fits in

The trajectory from week 10 onward depends on reaching and tolerating the maintenance dose, for most people, 2.4mg weekly, though the newer 7.2mg dose approved by the MHRA in early 2026 represents a higher ceiling for eligible patients. Results continue to compound through months four, five, and six, which is why how long Wegovy takes to work is often best understood across the full titration arc rather than any single point.

NICE's recommendation for semaglutide (TA875) includes a review at six months on the maintenance dose: if weight loss is less than 5%, continuing is reconsidered. That benchmark gives week 10 its proper context, it is a waypoint, not the measure that determines whether treatment is working. For more on what Wegovy includes as a treatment option, the Wegovy overview covers the licensed indications and how the medicine fits into a broader approach to weight management.

If you are considering starting, or are already mid-treatment and want a clinical conversation about your progress, a free consultation with our prescribers is the place to start. Every review at nume is carried out by a GPhC-registered Independent Prescriber, a clinician who reads your case personally. We also publish a Wegovy price comparison for those weighing up the cost side of private treatment, and if you want to understand how long you can go between Wegovy shots if a dose is delayed or your schedule changes, that guidance is available on this site alongside the about us page that sets out how our pharmacy and clinical team are structured if you want to understand who you would be dealing with.